DOTmed June 19, 2024
Boston Scientific has announced a definitive agreement to acquire Silk Road Medical for $27.50 per share, valuing the deal at approximately $1.16 billion, in an effort to expand its vascular portfolio with innovative stroke prevention technology.
Silk Road Medical specializes in a minimally invasive procedure called transcarotid artery revascularization (TCAR), which targets carotid artery disease. The condition, responsible for one-third of all strokes, involves the narrowing or blockage of carotid arteries due to plaque buildup. Traditional treatments include medical therapy, stent placement, or surgery, whereas TCAR offers an alternative by making a small incision in the neck, temporarily reversing blood flow to prevent dislodged plaque from reaching the brain, and placing a stent to stabilize plaque and prevent future strokes.
...Today's Sponsors
Today's Sponsor